Mark P. Schoenberg
Chief Medical OfficerDr. Mark P. Schoenberg, M.D. has been Chief Medical Officer of Urogen Pharma Ltd. since December 2017 and was its Medical Director since February 2016. He has Serves as Chief Medical Officer at Urogen Pharma, Inc. Dr. Schoenberg has years of experience in clinical practice and research focused on the care of patients with all forms of bladder cancer. Since April 2014, Dr. Schoenberg has been University Professor and Chairman of the Urology Department at The Montefiore Medical Center for The Albert Einstein College of Medicine of Yeshiva University. Prior to joining that, from 2005 to 2014, Dr. Schoenberg served as Director of Urologic Oncology and Bernard L. Schwartz Distinguished Professor of Urology at Johns Hopkins Hospital. Dr. Schoenberg is Member of Scientific Advisory Board of Tengion, Inc. Dr. Schoenberg is also the Past Chair of the Medical Advisory Board of the Bladder Cancer Advocacy Network, the author of The Guide to Living with Bladder Cancer, co-editor of The Textbook of Bladder Cancer, a contributor to Campbell’s Urology and a seminars editor of the journal Urologic Oncology. Dr. Schoenberg is a fellow of the American College of Surgeons, as well as a member of the American Association of Cancer Research, the Society of Urologic Oncology and the American Urological Association. Dr. Schoenberg received his M.D. (Alpha Omega Alpha) from the University of Texas Health Sciences Center and completed his residency in General Surgery and Urology at the Hospital of The University of Pennsylvania, where he served as Chief Resident and Urology Instructor, before completing basic research and clinical urologic oncology fellowships at Johns Hopkins under the auspices of The American Cancer Society. Dr. Schoenberg got his undergraduate degree from Yale University.
Positions
- Company NameUroGen Pharma Ltd.Stock CodeURGNPositionChief Medical OfficerColleagues
- EAElizabeth A. BarrettPresident, CEO & Director
- ASArie S. BelldegrunIndependent Chairman
- JDJason Drew SmithGeneral Counsel, Chief Compliance Officer & Corporate Secretary
- CDChristopher DegnanChief Financial Officer
- VIVincent I. PerroneSenior Director of Investor Relations
- HLHerbert LeporChairman of Scientific Advisory Board
- CMCynthia Marie ButittaIndependent Director
- LSLeana S. WenIndependent Director
